ZIP4 Is A Novel Molecular Target In Pancreatic Cancer | 7619
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Pancreatic cancer is one of the most difficult human cancers to treat due to the inability to detect
disease at an early stage and the lack of effective therapies. Although there has been some progress
in the use of improved diagnostic methods and development of novel targeted therapies, the overall
survival rate is not improved over the last decade. Pancreatic cancer remains the fourth leading cause of
cancer death in the United States, with an annual mortality nearly equivalent to the annual incidence.
Therefore, it is important to identify novel molecular markers and therapeutic targets in pancreatic
cancer that could lead to more effective treatment for this malignant disease. Our study indicates that a
dietary zinc transporter, ZIP4, regulates pancreatic cancer cell growth, tumor progression, and survival,
which assigns a new and important role for ZIP4. We have shown that ZIP4 is specifically overexpressed
in a majority of pancreatic cancer patients and contributes to pancreatic cancer pathogenesis and
progression. Silencing of ZIP4 significantly decreased the growth of pancreatic cancer, and increased
the survival rate of nude mice with orthotopic xeno grafts. Those results suggest that ZIP4 is a novel
therapeutic target for pancreatic cancer. However, the detailed mechanisms of how ZIP4 regulates
pancreatic cancer growth are not clear. Our studies suggest that ZIP4 overexpression causes increased
IL-6 transcription and STAT3 activation, and also leads to increased cyclin D1 expression, indicating
that ZIP4 might regulate pancreatic cell proliferation and tumor progression through the IL-6/STAT3
Dr. Min Li got his PhD from Emory University in 2002. He then moved on to Baylor College of Medicine and started his career in cancer research as an Assistant Professor in 2004. Dr. Li joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of Cancer Research Program. His research interests include pancreatic cancer and brain tumor. Dr. Li’s group is the first one to identify ZIP4 as a novel molecular target in pancreatic cancer. He has published more than 90 papers and serves as an editorial board member of many journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals